Mucosal Immunity of Mannose-modified Chitosan Microspheres Loaded with the Nontyepable Haemophilus Influenzae Outer Membrane Protein P6 in BALB/c Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Jun 10

PMID 35687548

Authors

Yushuai Ma

Ying Zhao

Rui Chen

Wanru Sun

Yanxia Zhang

Haixia Qiao

Yueli Chang

Shaoping Kang

Yutuo Zhang

Affiliations

Soon will be listed here.

Abstract

Nontypeable Haemophilus influenzae (NTHi) is a common opportunistic pathogen that colonizes the nasopharynx. NTHi infections result in enormous global morbidity in two clinical settings: otitis media in children and acute exacerbation of chronic obstructive pulmonary disease (COPD) in adults. Thus, there is an urgent need to design and develop effective vaccines to prevent morbidity and reduce antibiotic use. The NTHi outer membrane protein P6, a potential vaccine candidate, is highly conserved and effectively induces protective immunity. Here, to enhance mucosal immune responses, P6-loaded mannose-modified chitosan (MC) microspheres (P6-MCMs) were developed for mucosal delivery. MC (18.75%) was synthesized by the reductive amination reaction method using sodium cyanoborohydride (NaBH3CN), and P6-MCMs with an average size of 590.4±16.2 nm were successfully prepared via the tripolyphosphate (TPP) ionotropic gelation process. After intranasal immunization with P6-MCMs, evaluation of humoral immune responses indicated that P6-MCMs enhance both systemic and mucosal immune responses. Evaluation of cellular immune responses indicated that P6-MCMs enhance cellular immunity and trigger a mixed Th1/Th2-type immune response. Importantly, P6-MCMs also trigger a Th17-type immune response. They are effective in promoting lymphocyte proliferation and differentiation without toxicity in vitro. The results also demonstrate that P6-MCMs can effectively induce MHC class I- and II-restricted cross-presentation, promoting CD4+-mediated Th immune responses and CD8+-mediated cytotoxic T lymphocyte (CTL) immune responses. Evaluation of protective immunity indicated that immunization with P6-MCMs can reduce inflammation in the nasal mucosa and the lung and prevent NTHi infection. In conclusion, MCMs are a promising adjuvant-delivery system for vaccines against NTHi.

Citing Articles

Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases.

Sinani G, Sessevmez M, Senel S Pharmaceutics. 2024; 16(9).

PMID: 39339237 PMC: 11434819. DOI: 10.3390/pharmaceutics16091201.

Natural Polymeric Composites Derived from Animals, Plants, and Microbes for Vaccine Delivery and Adjuvant Applications: A Review.

Nordin A, Nur Husna S, Ahmad Z, Nordin M, Ilyas R, Azemi A Gels. 2023; 9(3).

PMID: 36975676 PMC: 10048722. DOI: 10.3390/gels9030227.

References

Wu M, Zhao H, Li M, Yue Y, Xiong S, Xu W . Intranasal Vaccination with Mannosylated Chitosan Formulated DNA Vaccine Enables Robust IgA and Cellular Response Induction in the Lungs of Mice and Improves Protection against Pulmonary Mycobacterial Challenge. Front Cell Infect Microbiol. 2017; 7:445. PMC: 5650621. DOI: 10.3389/fcimb.2017.00445. View

Sunakawa K, Takeuchi Y, Iwata S . [Nontypeable Haemophilus influenzae (NTHi) epidemiology]. Kansenshogaku Zasshi. 2011; 85(3):227-37. DOI: 10.11150/kansenshogakuzasshi.85.227. View

Pan Y, Li Y, Zhao H, Zheng J, Xu H, Wei G . Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm. 2002; 249(1-2):139-47. DOI: 10.1016/s0378-5173(02)00486-6. View

Fernandez S, Cisney E, Ulrich R . Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery. Clin Vaccine Immunol. 2013; 20(11):1690-6. PMC: 3837783. DOI: 10.1128/CVI.00215-13. View

Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher A, Davis S . Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001; 51(1-3):81-96. DOI: 10.1016/s0169-409x(01)00171-5. View

Khan M, Kaur R, E Pichichero M . Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children. FEMS Immunol Med Microbiol. 2012; 65(3):439-47. DOI: 10.1111/j.1574-695X.2012.00967.x. View

Michel L, Snyder J, Schmidt R, Milillo J, Grimaldi K, Kalmeta B . Dual orientation of the outer membrane lipoprotein P6 of nontypeable haemophilus influenzae. J Bacteriol. 2013; 195(14):3252-9. PMC: 3697637. DOI: 10.1128/JB.00185-13. View

Kang M, Kang S, Jiang H, Shin S, Lee D, Ahn J . In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur J Pharm Biopharm. 2006; 63(2):215-20. DOI: 10.1016/j.ejpb.2006.01.010. View

Zaharoff D, Rogers C, Hance K, Schlom J, Greiner J . Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine. 2007; 25(11):2085-94. PMC: 1890043. DOI: 10.1016/j.vaccine.2006.11.034. View

10.

Curotto E, Aros F . Quantitative determination of chitosan and the percentage of free amino groups. Anal Biochem. 1993; 211(2):240-1. DOI: 10.1006/abio.1993.1263. View

11.

Zhu L, Chen L, Cao Q, Chen D, Cui J . Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system. J Control Release. 2011; 152 Suppl 1:e190-1. DOI: 10.1016/j.jconrel.2011.08.082. View

12.

Kodama S, Suenaga S, Hirano T, Suzuki M, MOGI G . Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun. 2000; 68(4):2294-300. PMC: 97416. DOI: 10.1128/IAI.68.4.2294-2300.2000. View

13.

Staerk M, Tolouee S, Christensen J . Nontypable Septicemia and Urinary Tract Infection Associated with Renal Stone Disease. Open Microbiol J. 2018; 12:243-247. PMC: 6110053. DOI: 10.2174/1874285801812010243. View

14.

Wu J, Wang Y, Yang H, Liu X, Lu Z . Preparation and biological activity studies of resveratrol loaded ionically cross-linked chitosan-TPP nanoparticles. Carbohydr Polym. 2017; 175:170-177. DOI: 10.1016/j.carbpol.2017.07.058. View

15.

Wilk M, Mills K . CD4 T Cells Following Infection and Immunization: Implications for More Effective Vaccine Design. Front Immunol. 2018; 9:1860. PMC: 6095996. DOI: 10.3389/fimmu.2018.01860. View

16.

Mayr U, Kudela P, Atrasheuskaya A, Bukin E, Ignatyev G, Lubitz W . Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microb Biotechnol. 2011; 5(2):283-94. PMC: 3815788. DOI: 10.1111/j.1751-7915.2011.00316.x. View

17.

Chieppa M, Bianchi G, Doni A, Del Prete A, Sironi M, Laskarin G . Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol. 2003; 171(9):4552-60. DOI: 10.4049/jimmunol.171.9.4552. View

18.

DeMaria T, Murwin D, Leake E . Immunization with outer membrane protein P6 from nontypeable Haemophilus influenzae induces bactericidal antibody and affords protection in the chinchilla model of otitis media. Infect Immun. 1996; 64(12):5187-92. PMC: 174506. DOI: 10.1128/iai.64.12.5187-5192.1996. View

19.

Whittaker R, Economopoulou A, Gomes Dias J, Bancroft E, Ramliden M, Pastore Celentano L . Epidemiology of Invasive Haemophilus influenzae Disease, Europe, 2007-2014. Emerg Infect Dis. 2017; 23(3):396-404. PMC: 5382729. DOI: 10.3201/eid2303.161552. View

20.

Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View